INNO — Innocan Pharma Cashflow Statement
0.000.00%
- CA$47.87m
- CA$43.51m
- $29.44m
- 76
- 41
- 18
- 41
Annual cashflow statement for Innocan Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -9.95 | -10.1 | -3.89 | -4.25 | -0.262 |
Depreciation | |||||
Non-Cash Items | 5.75 | 4.39 | -1.68 | 1.1 | -0.149 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.474 | -0.969 | -0.531 | -0.793 | -1.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Cash from Operating Activities | -3.69 | -6.63 | -6.07 | -3.9 | -1.58 |
Capital Expenditures | 0 | -0.041 | -0.026 | -0.046 | -0.015 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -0.007 | -0.005 | -0.038 | 0.069 |
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0 | -0.048 | -0.031 | -0.084 | 0.054 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 4.02 | 15.3 | 0.125 | 2.92 | 2.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.365 | 8.71 | -6.1 | -1.06 | 1.12 |